SPARC: THE HIGH-RISK PHARMA INNOVATION BET 🧬

SPARC The next big pharmaceutical opportunity may come from discovering better medicines, not simply manufacturing more of them. Sun Pharma Advanced Research Company (SPARC) is focused on that innovation-driven opportunity. SPARC is a pharmaceutical research and development company working on novel drug delivery systems, differentiated formulations and innovative therapies. Its business is built around developing products that can potentially address unmet medical needs and create value through licensing and commercial partnerships. But this is not a conventional pharma business. Q2 FY27 consolidated performance: Revenue from operations: ₹30.03 crore, up approximately 282% YoY. Net loss: ₹24.39 crore, compared with a loss of ₹75.85 crore a year ago. H1 FY27 revenue: ₹69.95 crore. H1 FY27 net loss: ₹45.17 crore, versus ₹127.72 crore in H1 FY26. The losses have narrowed substantially year-on-year, but the company remains loss-making. Revenue also declined around 24.8% sequentially from Q1 FY27. Where could the opportunity come from? Successful clinical development of its drug candidates. Regulatory approvals in key markets. Licensing deals and partnerships with larger pharmaceutical companies. Commercialisation of differentiated drug delivery technologies. Milestone payments and potential royalties from successful products. The business flywheel: Research → Clinical trials → Regulatory approvals → Licensing → Commercialisation → Potential recurring royalties. However, the risks are substantial. Clinical trials can fail, regulatory approvals can be delayed, development costs can remain high and commercialisation may take years. Revenue can be unpredictable, while continued losses may require additional funding.